News | Stents Drug Eluting | May 31, 2018

Titanium-Nitride-Oxide Stent Superior to Bioabsorbable Drug-Carrier DES in Acute Coronary Syndrome Patients

Optimax TiNO-coated stent displayed better safety outcomes at 18 months without compromising target lesion revascularization

Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

May 31, 2018 – Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-nitride-oxide (TiNO)-coated Optimax stent was superior to the Synergy bioresorbable polymer coated metallic everolimus-eluting stent (EES) in acute coronary syndrome (ACS) patients. Results were presented by Pasi Karjalainen, M.D., Heart Center, Satakunta Central Hospital, Pori, Finland.

“At 18 months post-percutaneous coronary intervention (PCI), the TIDES-ACS results reveal that the Optimax nitride-oxide coated stent is superior in patients with acute coronary syndrome compared to one of the top drug-eluting stents used in current interventional cardiology,” stated Karjalainen.

Conducted in 12 international sites, this study randomised 1,491 ACS patients (2:1) to receive either TiNO-coated stents (n=989) or EES (n=502).

The co-primary endpoint (composite of cardiac death, re-infarction and major bleeding) occurred in 3.7 percent of patients receiving TiNO-coated stents, versus 7.8 percent of those receiving EES (superiority P=0.001).

For individual major adverse cardiac event (MACE) components at 18 months, both cardiac death (0.6 percent versus 2.6 percent, respectively; p=0.002) and non-fatal myocardial infarction (MI) (2.2 percent versus 5 percent, respectively; p=0.004) were observed less frequently with TiNO-coated stents. Ischemia-driven target lesion revascularization (TLR) occurred more frequently in the TiNO-coated stent arm, although this trend was not statistically significant (5.8 percent versus 4.4 percent, respectively; p=0.26 NS).

These results follow the previously reported 12-month primary endpoint results, where MACE occurred in 6.3 percent of patients receiving TiNO-coated stents, versus 7 percent of those receiving EES (p for non-inferiority <0.001).

“When considering the cumulative incidence of safety events, the Optimax stent displayed a 4.1 percent difference compared to Synergy, a significant advantage for patients treated with TiNO-coated stents,” said Karjalainen.  

In conclusion, for patients presenting with ACS, cobalt-chromium-based TiNO-coated stents were superior to platinum-chromium-based bioabsorbable polymer EES for the primary composite of safety outcome at 18-month follow-up without compromising the TLR rate (p=0.26 NS).   

“[The] TIDES-ACS trial is the first adequately powered head-to-head randomized comparison of contemporary bioactive stent technology with cutting-edge DES technology, in the setting of ACS. It provided sound evidence of superiority of the former, compared with the latter, for the composite of hard safety endpoints.” said Karjalainen, the principal investigator of this study.

“Based on this solid premise, we can advocate the use of [the] TiNO-coated BioActive Stent (BAS) as a worthwhile alternative to DES in ACS. It is our aspiration that stents based on this bioactive technology will be embraced by the upcoming Practice Guideline committees, as a viable and valid option for PCI in ACS patients." he added.

For more information: www.hexacath.com

Find links to other EuroPCR 2018 late-breaking trials.

Related Content

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp